A prospective, multicentre postmarketing surveillance to monitor safety associated with usage of Simponi® (golimumab injection 50mg) in Indian subjects with Rheumatoid Arthritis as per locally approved prescribing information

Trial Profile

A prospective, multicentre postmarketing surveillance to monitor safety associated with usage of Simponi® (golimumab injection 50mg) in Indian subjects with Rheumatoid Arthritis as per locally approved prescribing information

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 08 Sep 2016

At a glance

  • Drugs Golimumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Sponsors Johnson & Johnson
  • Most Recent Events

    • 08 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top